FlexCare Clinical Research, LLC (FlexCare) announced formation of the company, a clinical service provider focused on providing study visits in the home or alternate site settings via a network of clinicians.
FlexCare was created to meet demand from the biopharmaceutical industry to accelerate clinical trials and streamline study processes. Traditionally, clinical trials are conducted at investigative sites such as hospitals or clinics, where subjects are required to travel for protocol-related tests and assessments throughout the duration of the study. Consequently, for decades, subject recruitment and retention have become challenges in the timely completion of clinical trials. FlexCare’s service model is designed to take the study to the subject, where protocol activities can be conducted in their home or at other alternate locations. FlexCare’s services also hope to benefit pediatric or geriatric subjects, students and working adults who find participation in traditional studies inconvenient.
FlexCare centrally manages study visits that are conducted by its network of clinicians. Services offered by FlexCare include study drug administration, blood draws and other biologic sample collections, clinical assessments, questionnaires and training at the subject’s home or other convenient location.
With the company’s launch, Gail Adinamis was named to the role of chief executive officer. Concurrent with Adinamis’ appointment, Dr. Gizelle Baker was named chief operating officer and Dr. Debbie Wilkerson, chief scientific officer.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Regulatory Compliance With eCOAs
April 26th 2024In the fourth and final part of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses how the regulatory stance on electronic clinical outcome assessments has changed over the years and what it could look like in the future.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.